News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. EMA validates the Marketing Authorisation Application (MAA) for risdiplam for the proposed use in people living with SMA

    The European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for risdiplam for the proposed use in people living with SMA. Validation of the MAA confirms that the submission is accepted and begins the formal scientific evaluation process by EMA’s Committee for Medicinal Products for Human Use (CHMP). Following our request, Roche provided […]

    READ MORE

  2. Risdiplam approved for the treatment of SMA in the U.S.

    Following our request to receive updates about the risdiplam clinical development programme, Roche is delighted to share with us that the U.S. Food and Drug Administration (FDA) has approved risdiplam for the treatment of SMA in adults and children 2 months of age and older. In the U.S., Risdiplam’s brand name is Evrysdi™. The FDA […]

    READ MORE

  3. A Biogen community update on Spinraza NURTURE study

    Based on our request for an update, Biogen has provided us with the following information about new results from their NURTURE study, a study of pre-symptomatic patients with SMA, recently presented at the virtual Cure SMA Research & Clinical Care Meeting, which took place from 10th to 12th June 2020. NURTURE is an ongoing, Phase […]

    READ MORE